dc.creator | Tasoudis P.T., Arvaniti C.K., Adamou A.T., Belios I., Stone J.H., Horick N., Sagris D., Dalekos G.N., Ntaios G. | en |
dc.date.accessioned | 2023-01-31T10:06:45Z | |
dc.date.available | 2023-01-31T10:06:45Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1016/j.ejim.2022.04.004 | |
dc.identifier.issn | 09536205 | |
dc.identifier.uri | http://hdl.handle.net/11615/79624 | |
dc.description.abstract | Objective: To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. Data Sources: A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was performed according to the PRISMA statement. Study Selection: Randomized control trials (RCTs) comparing IL-6 inhibitors to SOC in hospitalized COVID-19 patients were deemed eligible. Data Extraction and Synthesis: Individual patient data were extracted from the Kaplan-Meier curves or were obtained from authors of included studies. Additionally, the reviewers independently abstracted data and assessed study quality of each eligible report. Results: Eleven studies were identified, incorporating 7467 patients (IL-6 inhibitors: 4103, SOC: 3364). IL-6 inhibitors were associated with decreased risk for death compared to SOC at the one-stage meta-analysis (Hazard Ratio [HR]: 0.75, 95% Confidence interval [CI]: 0.69–0.82, p<0.0001) and the two-stage meta-analysis (HR: 0.85, 95%CI: 0.77–0.93, p<0.001, I2 = 0.0%). Meta-regression analysis revealed that the difference in OS between the two groups was not influenced by the mean age of patients. At secondary meta-analyses, IL-6 inhibitors were associated with decreased odds for intubation OR:0.74, 95%CI:0.65–0.85, p<0.001, I2=0.0%). IL-6 inhibitors were associated with increased odds for discharge compared to SOC (OR:1.28, 95% CI:1.15–1.42, p<0.001, I2=0.0%). Conclusions and Relevance: This meta-analysis of individual patient data from randomized trials shows that IL-6 inhibitors significantly reduce the risk of death compared to SOC. IL-6 inhibitors are also associated with better outcomes in terms of intubation and discharge rates compared to SOC. © 2022 | en |
dc.language.iso | en | en |
dc.source | European Journal of Internal Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127959633&doi=10.1016%2fj.ejim.2022.04.004&partnerID=40&md5=f51f4a41c1b66d34d214ad9508419332 | |
dc.subject | antibiotic agent | en |
dc.subject | anticoagulant agent | en |
dc.subject | antiinfective agent | en |
dc.subject | antipyretic agent | en |
dc.subject | antiretrovirus agent | en |
dc.subject | antivirus agent | en |
dc.subject | azithromycin | en |
dc.subject | C reactive protein | en |
dc.subject | casirivimab plus imdevimab | en |
dc.subject | chloroquine | en |
dc.subject | convalescent plasma | en |
dc.subject | corticosteroid | en |
dc.subject | creatine kinase | en |
dc.subject | D dimer | en |
dc.subject | dexamethasone | en |
dc.subject | favipiravir | en |
dc.subject | glucocorticoid | en |
dc.subject | heparin | en |
dc.subject | hydroxychloroquine | en |
dc.subject | hydroxychloroquine sulfate | en |
dc.subject | immunomodulating agent | en |
dc.subject | lopinavir plus ritonavir | en |
dc.subject | low molecular weight heparin | en |
dc.subject | nonsteroid antiinflammatory agent | en |
dc.subject | oseltamivir | en |
dc.subject | paracetamol | en |
dc.subject | prednisolone | en |
dc.subject | remdesivir | en |
dc.subject | ritonavir | en |
dc.subject | sarilumab | en |
dc.subject | siltuximab | en |
dc.subject | tocilizumab | en |
dc.subject | interleukin 6 | en |
dc.subject | adult | en |
dc.subject | antiviral therapy | en |
dc.subject | Article | en |
dc.subject | asthma | en |
dc.subject | atrial fibrillation | en |
dc.subject | Brazil | en |
dc.subject | chronic kidney failure | en |
dc.subject | chronic obstructive lung disease | en |
dc.subject | clinical feature | en |
dc.subject | comorbidity | en |
dc.subject | coronary artery disease | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | data extraction | en |
dc.subject | diabetes mellitus | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | France | en |
dc.subject | heart failure | en |
dc.subject | hospital discharge | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | immunotherapy | en |
dc.subject | information retrieval | en |
dc.subject | intensive care unit | en |
dc.subject | intubation | en |
dc.subject | Italy | en |
dc.subject | Kaplan Meier method | en |
dc.subject | low drug dose | en |
dc.subject | male | en |
dc.subject | Medline | en |
dc.subject | meta analysis | en |
dc.subject | mortality | en |
dc.subject | mortality risk | en |
dc.subject | outcome assessment | en |
dc.subject | overall survival | en |
dc.subject | oxygen therapy | en |
dc.subject | patient coding | en |
dc.subject | proportional hazards model | en |
dc.subject | protein blood level | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | risk reduction | en |
dc.subject | Scopus | en |
dc.subject | survival rate | en |
dc.subject | systematic review | en |
dc.subject | thrombosis | en |
dc.subject | tuberculosis | en |
dc.subject | United Arab Emirates | en |
dc.subject | United Kingdom | en |
dc.subject | United States | en |
dc.subject | Coronavirinae | en |
dc.subject | drug therapy | en |
dc.subject | Coronavirus | en |
dc.subject | COVID-19 | en |
dc.subject | Humans | en |
dc.subject | Interleukin Inhibitors | en |
dc.subject | Interleukin-6 | en |
dc.subject | Randomized Controlled Trials as Topic | en |
dc.subject | Elsevier B.V. | en |
dc.title | Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials | en |
dc.type | journalArticle | en |